Hajime Mizukami

Dr. Hajime Mizukami


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2018 in Molecules
Verified
Journal Article
Open access
PDF file
MNMai Nagasaka
Mai Nagasaka
RHRyoko Hashimoto
Ryoko Hashimoto
YIYasumichi Inoue
Yasumichi Inoue
KIKan'ichiro Ishiuchi
Kan'ichiro Ishiuchi
MMMichiyo Matsuno
Michiyo Matsuno
Yasumichi InoueYasumichi Inoue
Yasumichi Inoue
The p53 tumor suppressor plays critical roles in cell cycle regulation and apoptotic cell death in response to various cellular stresses, thereby preventing cancer development. Therefore, the activation of p53 through small molecules is an attractive therapeutic strategy for the treatment of cancers retaining wild-type p53. We used a library of 700 Myanmar wild plant extracts to identify small molecules that induce p53 transcriptional activity. A cell-based screening method with a p53-responsive luciferase-reporter assay system revealed that an ethanol extract of Oroxylum indicum bark increased p53 transcriptional activity. Chrysin was isolated and identified as the active ingredient in the O. indicum bark extract. A treatment with chrysin increased p53 protein expression and the p53-mediated expression of downstream target genes, and decreased cell viability in MCF7 cells, but not in p53-knockdown MCF7 cells. We also found that chrysin activated the ATM-Chk2 pathway in the absence of DNA damage. Hence, the inactivation of the ATM-Chk2 pathway suppressed p53 activation induced by chrysin. These results suggest the potential of chrysin as an anti-cancer drug through the activation of p53 without DNA damage.

1 March 2005 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
KHKazutaka Hirakawa
Kazutaka Hirakawa
MYMaim Yoshida
Maim Yoshida
ANAkito Nagatsu
Akito Nagatsu
HMHajime Mizukami
Hajime Mizukami
VRVIRENDRA RANA
VIRENDRA RANA
SKShosuke Kawanishi
Shosuke Kawanishi

24 February 2021 in Journal of Natural Medicines
Verified
Journal Article
Closed access
PDF file
TMTeruki Matsumoto
Teruki Matsumoto
MMMichiyo Matsuno
Michiyo Matsuno
NINorihito Ikui
Norihito Ikui
YMYoshiyuki Mizushina
Yoshiyuki Mizushina
YOYume Omiya
Yume Omiya
HMHajime Mizukami
Hajime Mizukami

27 August 2019 in Molecules
Verified
Journal Article
Open access
PDF file
SNSakiko Nishikawa
Sakiko Nishikawa
IYItoh Yuka
Itoh Yuka
MTMuneshige Tokugawa
Muneshige Tokugawa
Yasumichi InoueYasumichi Inoue
Yasumichi Inoue
KNKen-ichi Nakashima
Ken-ichi Nakashima
HHHidetoshi Hayashi
Hidetoshi Hayashi
In response to cellular stresses, activating transcriptional factor 4 (ATF4) regulates the expression of both stress-relieving genes and apoptosis-inducing genes, eliciting cell fate determination. Since pharmacological activation of ATF4 exerts potent anti-tumor effects, modulators of ATF4 activation may have potential in cancer therapy. We herein attempted to identify small molecules that activate ATF4. A cell-based screening to monitor TRB3 promoter activation was performed using crude drugs used in traditional Japanese Kampo medicine. We found that an extract from Sophora flavescens roots exhibited potent TRB3 promoter activation. The activity-guided fractionation revealed that kurarinone was identified as the active ingredient. Intriguingly, ATF4 activation in response to kurarinone required PKR-like endoplasmic reticulum kinase (PERK). Moreover, kurarinone induced the cyclin-dependent kinase inhibitor p21 as well as cytostasis in cancer cells. Importantly, the cytostatic effect of kurarinone was reduced by pharmacological inhibition of PERK. These results indicate that kurarinone triggers ATF4 activation through PERK and exerts cytostatic effects on cancer cells. Taken together, our results suggest that modulation of the PERK-ATF4 pathway with kurarinone has potential as a cancer treatment.

1 January 2001 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Open access
MMMichiyo Matsuno
Michiyo Matsuno
ANAkito Nagatsu
Akito Nagatsu
YOYukio Ogihara
Yukio Ogihara
HMHajime Mizukami
Hajime Mizukami
A simple method to synthesize (+/-)-2-O-(4-coumaroyl)-3-(4-hydroxyphenyl)lactic acid (1), a key intermediate in rosmarinic acid biosynthesis in higher plant cells, was established by condensation of protected 4-coumaric acid and (+/-)-3-(4-hydroxyphenyl)lactic acid followed by deprotection. A stable supply of 1 thus attained will lead to biochemical and molecular biological characterization of later steps of rosmarinic acid biosynthesis.

5 May 2022 in Plants
Verified
Journal Article
Open access
PDF file
KKKakuki Kato
Kakuki Kato
AHAsako Horiba
Asako Horiba
HMHajime Mizukami
Hajime Mizukami
HHHiroaki Hayashi
Hiroaki Hayashi
KTKazuyoshi Terasaka
Kazuyoshi Terasaka
Glycyrrhizin (GL), a triterpene compound produced by Glycyrrhiza species, is a crucial pharmacologically active component of crude drugs. In contrast to the biosynthesis of GL in plants, little is known about GL transport and accumulation in plants. The transport mechanism of GL was characterized using cultured cells of Glycyrrhiza glabra. Cultured cells of G. glabra efficiently incorporated exogenously supplied GL. Proton pump inhibitors, such as probenecid and niflumic acid, as well as a protonophore (carbonylcyanide m-chlorophenylhydrazone), markedly inhibited GL uptake by cultured cells, whereas vanadate exhibited a moderate inhibition. Furthermore, GL transport by G. glabra tonoplast vesicles is dependent not on a H+-electrochemical gradient but MgATP and is markedly inhibited by vanadate. These results suggest that GL uptake by cultured cells is mediated by a H+-symporter in the plasma membrane and an ATP-binding cassette transporter, which has high specificity for the aglycone structure of GL on the tonoplast.